Transition and Lilly may cease development of gastrin-based antidiabetics following Phase II failure
This article was originally published in Scrip
Executive Summary
Canadian firm Transition Therapeutics and Lilly may end their diabetes R&D agreement exploring gastrin-based therapies after the lead type 2 diabetes candidate TT-223 failed to meets its Phase II efficacy endpoints.